Wall Street brokerages expect Teva Pharmaceutical Industries Limited (NYSE:TEVA) to announce $5.63 billion in sales for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Teva Pharmaceutical Industries Limited’s earnings, with estimates ranging from $5.58 billion to $5.72 billion. Teva Pharmaceutical Industries Limited posted sales of $5.56 billion in the same quarter last year, which suggests a positive year-over-year growth rate of 1.3%. The company is expected to issue its next quarterly earnings report on Tuesday, November 21st.

According to Zacks, analysts expect that Teva Pharmaceutical Industries Limited will report full-year sales of $5.63 billion for the current financial year, with estimates ranging from $22.40 billion to $23.01 billion. For the next year, analysts expect that the company will report sales of $22.10 billion per share, with estimates ranging from $21.39 billion to $22.90 billion. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Teva Pharmaceutical Industries Limited.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.06 by ($0.07). The business had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The firm’s revenue was up 12.9% on a year-over-year basis. During the same period in the prior year, the company posted $1.25 earnings per share.

A number of research firms have issued reports on TEVA. BidaskClub cut Teva Pharmaceutical Industries Limited from a “sell” rating to a “strong sell” rating in a research note on Thursday. Sanford C. Bernstein decreased their target price on Teva Pharmaceutical Industries Limited from $28.00 to $20.00 and set a “market perform” rating for the company in a research note on Thursday. Cantor Fitzgerald reissued a “hold” rating and issued a $17.00 target price on shares of Teva Pharmaceutical Industries Limited in a research note on Monday, September 18th. Royal Bank Of Canada decreased their target price on Teva Pharmaceutical Industries Limited from $21.00 to $15.00 and set an “underperform” rating for the company in a research note on Monday, September 18th. Finally, Maxim Group reissued a “hold” rating and issued a $15.50 target price on shares of Teva Pharmaceutical Industries Limited in a research note on Thursday, September 14th. Five equities research analysts have rated the stock with a sell rating, nineteen have issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $30.91.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded up 0.23% during midday trading on Friday, reaching $17.19. The company had a trading volume of 8,986,279 shares. The firm’s market cap is $17.47 billion. The company’s 50-day moving average is $18.13 and its 200-day moving average is $28.20. Teva Pharmaceutical Industries Limited has a 52-week low of $15.22 and a 52-week high of $51.51.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th were paid a $0.085 dividend. The ex-dividend date was Friday, August 25th. This represents a $0.34 annualized dividend and a yield of 1.98%. Teva Pharmaceutical Industries Limited’s dividend payout ratio is -15.36%.

Large investors have recently added to or reduced their stakes in the business. San Francisco Sentry Investment Group CA bought a new stake in Teva Pharmaceutical Industries Limited in the second quarter valued at approximately $106,000. Bronfman E.L. Rothschild L.P. grew its position in shares of Teva Pharmaceutical Industries Limited by 7.8% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock valued at $116,000 after purchasing an additional 261 shares during the last quarter. Kistler Tiffany Companies LLC grew its position in shares of Teva Pharmaceutical Industries Limited by 74.7% in the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock valued at $122,000 after purchasing an additional 1,571 shares during the last quarter. FNY Managed Accounts LLC acquired a new position in shares of Teva Pharmaceutical Industries Limited in the first quarter valued at approximately $123,000. Finally, Sterling Investment Advisors Ltd. grew its position in shares of Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock valued at $125,000 after purchasing an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 56.76% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Analysts Expect Teva Pharmaceutical Industries Limited (TEVA) Will Announce Quarterly Sales of $5.63 Billion” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/09/23/analysts-expect-teva-pharmaceutical-industries-limited-teva-will-announce-quarterly-sales-of-5-63-billion.html.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries Limited (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.